Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions

Abstract

Nosema ceranae can cause major problems, such as immune suppression, gut epithelial cell degeneration, reduced honeybee lifespan, or suddenly colony collapse. As a novel approach in therapy, we hypothesize the stable gastric pentadecapeptide BPC 157 in honeybee therapy, to control N. ceranae invasions in apiary conditions: BPC 157 treated sugar syrup (0.25 L sugar syrup supplemented with 0.1 μg/ml BPC 157), as well as the pure sugar syrup (0.25 L sugar syrup; control), was administered to honeybee colonies in feeders situated under the roof of the hives, during 21 consecutive days, at the end of beekeeping season. The strength of honeybee colonies was increased 20 and 30 days after initial feeding with BPC 157 supplement (Day 1, 36.100 ± 698; Day 20, 64.860 ± 468; Day 30, 53.214 ± 312 estimated number of honeybees), in field conditions. The similar successful outcome occurs with the N. ceranae spore loads counted in the homogenates of sampled adult honeybees (Day 1, 6.286 ± 2.336; Day 20, 3.753 ± 1.835; Day 30, 2.005 ± 1.534 million spores/bee). Accordingly, with the noted increased strength of the colonies fed with sugar syrup supplemented with BPC 157, the number of N. ceranae spores per honeybee gradually decreased as well. Besides, honeybees infected with N. ceranae fed with sugar syrup exhibited severe damage of midgut wall layers and epithelial cells. By contrast, in honeybees infected with N. ceranae fed with sugar syrup supplemented with BPC 157, all damages were markedly attenuated, damages of the outer muscular coat, in particular. In conclusion, the results of the first field trial on diseased honeybee colonies with BPC 157 indicate significant therapeutic effects with the used oral therapy with BPC 157 supplementation.

Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future

“…But more important is the practical indicative evidence that even with the majority of studies on BPC 157 done on rodents given injection of the supplement, there are considerable number of the studies, particularly in gastrointestinal research, intragastric application or per-oral application in drinking water, correspondingly effective. 12,41,43,48,51,54,55,58,59,[61][62][63][82][83][84][85]89,[91][92][93]98,114,116,117,[143][144][145][146][147][149][150][151][152][153][154][155] In reality, in particular along with its safe profile, LD-1 not achieved, and no adverse effects in clinical trials, [1][2][3][4][5][6][7][8][9][10][11]…”

Physiological and Immunological Status of Adult Honeybees (Apis mellifera) Fed Sugar Syrup Supplemented with Pentadecapeptide BPC 157

“…In a previous study, we reported about the first appliance of stable gastric pentadecapeptide BPC 157 to honeybee colonies with achieved significant therapeutic effects against Nosemosis type C [ 1 ], caused by microsporidium Nosema ceranae [ 2 ]. We hypothesized and confirmed that BPC 157, as a new way of honeybee therapy, can be used to counteract N. ceranae invasions in field conditions and increase colonies strength [ 1 ].…”

Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats

“…Finally, considering the presented and previous findings in fistula research [5][6][7][8][9][10], this study should overwhelm the general point that animal studies per se may be cautious, and fistulas studies; in particular, regarding their results and the relative paucity of the BPC 157 clinical data [1][2][3][4]. On the other hand, BPC 157 was proved to be efficacious in the ulcerative colitis, both in clinical settings [65,66], and in the experimental rats studies, in the ischemic/reperfusion vascular ulcerative colitis studies [60] and other ulcerative colitis models, induced by TNBS [67], cysteamine, surgery [31,68,69], NSAIDs [30,[70][71][72][73], or major vessel occlusion [48][49][50][51][52]59], including various species [74], and fistulas as complications (for review see, i.e., [3]). A particular point for revealing and applying this concept in practice (BPC 157's beneficial effect on various fistulas toward counteraction of the vesicovaginal fistulas in particular) is a very safe profile (LD1 could be not achieved) [17], a point recently confirmed in a large study of the Xu and collaborators [75].…”